Jean-Christophe Tellier, the new president of EFPIA, tells the Pink Sheet why "connected health care" is the key to the future of innovation, how stakeholders should work collaboratively to address the affordability of new therapies, and why Brexit must not lead to fragmentation of the health care network in Europe.
The future of pharmaceutical innovation lies in a collaborative, multidisciplinary approach where all stakeholders work together in a more “connected” health care environment, making full use of human and cell biology and resources like real world evidence, big data and advanced analytics to develop treatments that address the fundamental causes of disease.
Greater cooperation and dialogue is the key to tackling issues like the affordability of new drugs in the face of...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
